BWX Technologies said Wednesday it has pushed back to mid-2022 its schedule for beginning commercial output of the medical isotope molybdenum-99 (Mo-99), partly due to supply issues created by the COVID-19 pandemic.
Discussing the company’s latest earnings in…
SUBSCRIBER ACCESS
Thank you for visiting
RadWaste Monitor!
You must be logged in as a subscriber to view this page.
